Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Live Q&A: Best Practices for Applying Recent Clinical Trial Data and Individualized Treatment to Fight EDS in OSA: A Three-Part BriefCase Series

Premiere Date: Tuesday, July 19, 2022

This activity will offer CE credit for:

1. Medicine (accme)
2. Nursing (ANCC)
3. Pharmacy (acpe)
4. PA (aapa)

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, July 19, 2023
Note: Credit Is No Longer Available

Faculty

Richard K. Bogan, MD, FCCP, FAASM (Moderator) Associate Clinical Professor University of South Carolina Medical School, Columbia, SC Medical University of South Carolina, Charleston, SC Principal, Bogan Sleep Consultants, LLC Charleston, SC

Russell Rosenberg, PhD  Chief Science Officer and CEO NeuroTrials Research, Inc. Atlanta, GA

Terri E. Weaver, PhD, RN, FAAN, ATSF, FAASM  Dean Emerita Professor Emerita of Biobehavioral Nursing Science College of Nursing University of Illinois Chicago Chicago, IL Professor Emerita of Nursing University of Pennsylvania Philadelphia, PA

Statement of Need

Obstructive sleep apnea (OSA)-related excessive daytime sleepiness (EDS) is about more than being sleepy. OSA-related EDS has been shown to impact work performance, work presenteeism and absenteeism, cognitive dysfunction, physical health, and functioning, occupational and driving accidents, personal relationships, and subsequently health-related quality of life (HRQoL). Treatment planning in patients with OSA-related EDS is highly specialized, and often poses a significant challenge to clinicians, considering the psychiatric and medical comorbidities that can complicate treatment decisions.

Nonstimulant therapies have emerged to offer sustained long-term efficacy with favorable safety and tolerability profiles and are an important addition to the treatment armamentarium. An awareness of clinical trial updates on available therapies and successful navigation of their implementation into practice is imperative.

This live Q&A session is your opportunity to ask faculty experts about the extensive burden imposed by OSA-related EDS, strategies for personalizing treatment, and practical application of recent clinical trial data to optimize patient outcomes.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Recognize the impact and burden of OSA-related EDS on HRQoL and work productivity.
• Position treatment strategies for OSA-related EDS based on individual patient profiles.
• Apply data from recent clinical trials to optimize treatment decision-making.

Financial Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals, Inc.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep, pulmonology, psychiatry, neurology and/or primary care

Credit Information

Specific CE Credit information is not available at this time. Please check again soon!

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports the following financial relationships:

Consultant: Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.

Dr. Rosenberg reports the following financial relationships:

Advisory Board: Harmony Biosciences, LLC

Research Support: Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: Jazz Pharmaceuticals, Inc.

Dr. Weaver reports the following financial relationships:

Advisory Board: Idorsia Pharmaceuticals Alliance for Sleep

Consultant: Bayer and Eli Lilly and Company

Other Financial Support: Axsome Therapeutics, Inc.; Bayer AG; Clinical Outcomes Solutions; Cook Medical; Eli Lilly and Company; Functional Outcomes of Sleep Questionnaire (FOSQ); Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; LivaNova PLC; Nyxoah; Philips Respironics; ResMed; ResMed Germany; RWS; Signant Health; Signifier Medical Technologies; Stratevi; Valis Biosciences Inc.; and Verily Life Sciences

The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

Marlon (Tony) Graham, MD (peer reviewer)

Kashemi D. Rorie, PhD (planning committee)

Evan Luberger (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).